Mackenzie Financial
TSHA icon

Mackenzie Financial’s Taysha Gene Therapies TSHA Stock Holding History

Mackenzie Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,308
Closed -$75.2K – 1754
2025
Q4 		$75.2K Buy
13,308
+2,094
+19% +$10.2K ﹤0.01% 1609
2025
Q3 		$36.7K Hold
11,214
– – ﹤0.01% 1667
2025
Q2 		$25.9K Buy
11,214
+1,214
+12% +$2.64K ﹤0.01% 1669
2025
Q1 		$13.9K Hold
10,000
– – ﹤0.01% 1657
2024
Q4 		$17.3K Hold
10,000
– – ﹤0.01% 1686
2024
Q3 		$20.1K Buy
+10,000
New +$21.9K ﹤0.01% 1564

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial's TSHA Position: Q1 2026 in Review

Mackenzie Financial sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 13,308 shares — an estimated $75.2K sold.

Mackenzie Financial first reported a position in TSHA in Q3 2024 and held it in 6 quarters. The position peaked at $75.2K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Mackenzie Financial reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 13,308 Taysha Gene Therapies shares in Q1 2026, an estimated $75.2K.
  • Mackenzie Financial first reported a position in Taysha Gene Therapies in Q3 2024 and held it in 6 quarters.
  • Mackenzie Financial's Taysha Gene Therapies position peaked at $75.2K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.